Actually RBC did get back on to ask the final question. It looks like the transcript changed "cohort" to COVID but the the question referred to 9930
Your final question comes from the line of Brian Abrahams with RBC Capital Markets.
Hi, yes, sorry. It's Leo on for Brian again. I think I got disconnected mid-question. Hopefully, you haven't answered it already. Yes, so I'm looking at the press release, it seems like you're going forward with the 200 milligram and 400 milligram doses in the low dose COVID patients by investigator assessment and also that the next studies skipping over the low dose. So should we take this to mean that the ultimate go forward dose is going to be in this higher dosing range? Are you still considering multiple doses? And how much window do you potentially have to push above 400 milligrams? And lastly, can you frame an expectation for what we might expect in naive versus poor responders?
Sure. Let's start with your last question first. The underlying cause of the disease is identical. And in correspondence, any naive subjects, in fact is identical and the activity of the drug will be identical. And therefore we expect that you can extrapolate the data we're generating in naive across the board in TNH. So that's actually a very important point. There's no fundamental difference in the biology and what -- the difference is the extent of optimization and extra vascular hemolysis that varies between subjects. That of course, you can't control with a C5 inhibitor and you have to have a proximal inhibitor to do it. With regard to dosing, the principal goal of this initial study is to select one dose to move forward. So that's our goal. Yes, we expect that will be in the higher dose range, not the lower dose range, we've already ruled out the 50 milligram and 100 milligram doses and the peak pharmacodynamics that we shared in May, it's impossible for me to distinguish the effect of 200 and 400. But, you know, what I'd like to see is the LDH and the other parameters, and then we'll make a decision.
Yes, remember the goal is to get as many patients into or close to the normal range with mono-therapy, so that's the goal.
Got it. Thank you.